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Abstract 
Background: Evaluation of novel cellular therapies in preclinical large animal models 
and patients is currently hampered by the lack of suitable imaging approaches that allow 
for long term monitoring of viable transplanted cells. The present study was designed to 
evaluate sodium iodide symporter (NIS) transgene imaging as a novel approach to follow 
long term in vivo survival, engraftment and distribution of human induced pluripotent stem 
cell (hiPSC) derivatives in a pig model of myocardial infarction. 
Methods and Results: Transgenic hiPSC lines stably expressing a fluorescent reporter 
and NIS (NISpos-hiPSCs) were established. Iodide uptake, efflux and cell viability of 
NISpos-hiPSCs was assessed in vitro. 10 ± 2 days after induction of myocardial infarction 
by transient occlusion of the left anterior descending artery, catheter-based 
intramyocardial injection of NISpos-hiPSCs guided through 3D NOGA™ mapping was 
performed. Longitudinal dual isotope SPECT-CT imaging was applied using 123I to follow 
donor cell survival and distribution, and 99mTC-tetrofosmin for myocardial perfusion 
imaging. 
In vitro, iodide uptake in NISpos-hiPSCs was increased 100-fold above non-transgenic 
controls. In vivo, viable NISpos-hiPSCs could be visualized at the injection sites for up to 
15 weeks. This was confirmed through immunohistochemistry demonstrating that hiPSC-
derived endothelial cells contributed to intramyocardial vascularisation. Up to 12-15 
weeks after transplantation, no undifferentiated hiPSCs or teratoma were detected. 
Conclusions: The present study describes for the first time the feasibility of repeated 
long term in vivo imaging of viability and tissue distribution of cellular grafts in the heart 
and other organs of large animals. Moreover, this is the first report demonstrating 
vascular differentiation and long term engraftment of hiPSCs in a large animal model of 
myocardial infarction. NISpos-hiPSCs represent a valuable tool to monitor and improve 
current cellular treatment strategies in clinically relevant large animal models. 
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Introduction 
Stem cell-based therapies are being actively explored as a potentially innovative 
therapeutic strategy for various genetic and acquired diseases. Recently, the possibility to 
reprogram human somatic cells into induced pluripotent stem cells (hiPSCs) that are able 
to differentiate into all cell lineages present in the heart1-4 has opened novel opportunities 
for myocardial repair. With respect to the potential therapeutic application of pluripotent 
stem cell derivatives, major progress has been achieved concerning scalable cell 
production5, 6 and more efficient and specific differentiation into cell types of interest.7 
 However, there are still major hurdles and risks to overcome with regard to 
pluripotent stem cell-based heart repair. These include safety risks, especially the 
potential of teratoma and tumor formation,2 low cell retention and engraftment rates,8-11 
and the general question of whether engraftment of hiPSC after simple intramyocardial 
cell injection leads to formation of functional tissue, such as de novo vasculature or 
myocardium, and results in significant clinical benefits.12 Although some of these issues 
can be addressed in vitro or in appropriate small animal models, others will require 
exploration in large animal models, which are more similar to humans.13 Transplanted 
human cardiomyocytes, for example, are unlikely to fully functionally integrate with rodent 
myocardium due to highly dissimilar beating rates.11 Therefore, meaningful assessment 
of human cells for heart repair has to be demonstrated in large animal models such as 
dogs, pigs or monkeys.13 
 Clearly, advanced imaging technologies allowing for longitudinal tracking of cellular 
grafts ideally enabling monitoring of donor cell survival, proliferation, distribution or even 
differentiation are crucial for (pre-)clinical evaluation of novel cell-based therapeutics.14 At 
present, transgene based imaging approaches that fulfill these requirements are mainly 
restricted to far-red fluorescence reporters or photon-emitting technologies, in particular 
based on luciferase expression. Unfortunately limited tissue penetration restricts 
application of these technologies to small animal models, only.15 
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 Most or previous large animal studies applied magnetic resonance imaging (MRI) 
technology to detect nanoparticle-labelled cells.16 Main disadvantage of this approach is 
the inability to discriminate vital donor cells from nanoparticle-loaded cell debris or 
recipient’s cells such as macrophages, which can actively incorporate cell debris and 
released nanoparticles by phagocytosis.16 In other studies direct radionuclide labeling of 
cells was performed e.g. through fluorine 18-fluorodeoxyglucose (18F-FDG), Indium-111 
(In111)-oxine, 64Cu-PTSM or technetium-99 (99mTc)-Hexamethylprophylene amine oxine.16 
Limitations of the latter techniques include isotope half-time- and label-retention-
dependent loss of signal strength.16 In addition, direct labeling strategies with 
nanoparticles or radionuclides, particularly for In111, have been reported to affect (stem-) 
cell vitality.16 
In a first pilot study to overcome these critical drawbacks, herpes simplex 
thymidine kinase (HSVtk)-mediated phosphorylation of [18F] FHBG was evaluated as a 
transgene-based imaging approach in large animals,17, 18 but detection of transplanted 
cells was reported several hours after cell injection, only. 
Another promising approach has recently been developed,19 which permits 
detection of viable transplanted cells by positron emission tomography (PET) or single 
photon emission computed tomography (SPECT) after iodide (123I) or 99mTc radiotracer 
administration. This technology relies on the expression of a transgenic sodium-iodide-
symporter (NIS)20 in transplanted donor cells. Physiological expression of NIS in the adult 
organism is restricted to the thyroid, stomach, choroids plexus and salivary gland and is 
not detectable in limbs, brain or other internal organs such as the heart.20 NIS-mediated 
iodide accumulation in the thyroid is an active transport process that occurs at the 
basolateral plasma membrane of the thyroid follicular cells against the iodide 
electrochemical gradient stimulated by thyroid-stimulating hormone (TSH), and can be 
specifically inhibited by perchlorate. Clinically, NIS expression provides the basis for the 
effective diagnostic of thyroid cancer and its metastases by iodide isotope 
administration.20 
CIRCULATIONAHA/2011/087684 
 
 
7
The technology provides important advantages with respect to clinical application 
for longitudinal tracking of stem cell grafts. This includes the lack of immunogenicity of the 
human NIS transgene and the fact that SPECT scanning of radiotracers such as 99mTc 
and 123I is widely available at relatively low costs and approved by the responsible 
regulatory authorities such as the Food and Drug Administration. Moreover, recent 
progress in quantification of tracer signals using clinical SPECT systems21 underlines the 
potential of this approach for tracking cellular transplants in large animals and patients. 
To date, however, the strategy was evaluated, only, in a small animal model focused on 
detection of acute cell retention following administration of heart-derived stem cells.19 
Here we demonstrate the applicability of this technology for in vivo monitoring of cellular 
grafts in a pig model of myocardial infarction. SPECT-CT imaging results revealed 
successful in vivo donor cell labeling by intracoronary iodide administration 5 days or 12 / 
15 weeks after intramyocardial cell transplantation. These data were confirmed by 
immunohistochemistry on harvested tissue providing unequivocal evidence for long term 
survival, engraftment and differentiation of transplanted human iPSC derivatives. 
CIRCULATIONAHA/2011/087684 
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Methods 
Culture of hiPSCs 
Conventional culture of hiPSCs was performed as previously described.1 Mass cell 
generation of NISpos-hiPSCs in suspension cultures was performed as previously 
described.5, 6 
 
Generation of sodium-iodide symporter transgenic hiPSC (NISpos-hiPSC) lines 
See supplements for details. 
 
Characterization of NISpos-hiPSCs 
See Figure 1 and supplements for details. 
 
Iodide uptake and efflux 
See supplements for details. 
 
Ex vivo cardiac SPECT-CT imaging 
For assessing the SPECT-CT detection limit in terms of prelabelled NISpos-hiPSCs, cells 
were incubated for 90 minutes with 1 MBq 123I per 1 x 106 cells. After vigorous washing, 
serial cell dilutions comprising a total of 1 x 104, 1 x 105, 5 x 105, 1 x 106, 3 x 106, 6 x 106 
or 1.2 x 107 labelled cells were injected into the lateral and septal wall of the left ventricle. 
The 123I signal was visualized through a dual-detector hybrid SPECT-CT (Infinia 
Hawkeye, GE Healthcare). In order to mimic in vivo imaging, heart derived 123I signals 
were recorded through a dissected pig chest that was placed above the heart to mimic 
signal attenuation. 
 
Large animal model 
Female landrace pigs (Large White Duroc, Sidler, Zurich, Switzerland; n = 13; 25 - 30 kg; 
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aged 8 - 10 weeks) were investigated in the present study. Animals were 
immunosuppressed with cyclosporine A (Novartis Pharmaceuticals, East Hanover, New 
Jersey; 10 mg / kg body weight daily) and prednisolone (Pfizer, Zurich, Switzerland; 2.5 
mg / kg body weight daily) starting 5 days before hiPSC transplantation until animals 
were sacrificed. Furthermore, all animals received 2 x 400 mg / d dronedarone at the first 
pre-operative and operative day, and 2 x 200 mg / d from the first post-operative day until 
the end of the study. All procedures were approved by the responsible local authorities 
and performed according to the Guide to the Care and Use of Experimental Animals 
published by the U.S. National Institutes of Health (NIH Publication 85-23, reviewed 
1996). A detailed description of the study design is shown in Figure 2. 
 
Induction of myocardial infarction 
Myocardial infarction was created by inflating the balloon for 180 min in the mid-segment 
of the LAD followed by reperfusion. See supplements for details. 
 
Electromechanical mapping 
3D NOGA™ mapping (Biologics Delivery Systems, Biosense Webster, Johnson & 
Johnson, Irvindale CA) was performed 10 ± 2 days after induction of myocardial infarction 
to assess electrophysiological tissue viability patterns and wall motion abnormalities. The 
catheter was placed through the right carotid sheet across the aortic valve into the left 
ventricle. By navigating the catheter along the endocardium, the local intracardiac 
electrogram together with the wall motion was recorded from its tip at multiple 
endocardial sites, and detailed three-dimensional electromechanical maps of the left 
ventricle were generated. The unipolar voltage values were colour-coded (visualizing 
infarct zones as red and viable tissue as green to purple) and superimposed on the three-
dimensional geometry of the map. NOGA™ mapping and injections were performed as 
previously described.22 
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Intramyocardial cell injections 
1 x 108 hiPSCs were labelled with 100 Mbq of 123I (1 Mbq = 1 x 106 cells) for 90 min prior 
to cell injection. Subsequently, cells were washed twice in PBS and were resuspended in 
PBS as delivery medium, which was supplemented with fluorospheres (Molecular 
Probes) to enable unequivocal identification of the cell injection sites under UV light 
during tissue sampling in sacrificed animals (See Supplemental Figure 1). Cell injection 
was performed with a 8F MyoStar injection catheter (Biosense-Webster) using a 27-G 
needle as follows: three sites with each eight single 250 μl injections were selected (left 
ventricle anterior wall: 50 million control cells (human mesenchymal stem cells, hMSCs), 
lateral and septal wall: 50 million NISpos-hiPSCs, or 50 million NISpos-hiPSCs mixed with 
50 million hMSCs). Control animals received PBS injections at corresponding injection 
sites. Exact positions of individual injection sites were documented by NOGA™ mapping. 
 
Computed tomography angiography 
For cardiac computed tomography angiography 1 ml / kg body weight iodixanol 
(Visipaque 320 mg / ml, GE Healthcare, Bucks, UK) at a flow rate of 4 - 5 ml / s followed 
by 50 ml saline solution was injected into the ear vein via a 20-gauge catheter. All scans 
were performed using the 64-detector CT-component (LightSpeed VCT, GE Healthcare) 
of a SPECT-CT scanner with prospective ECG-triggering, as previously established and 
described in detail.23 Images were analysed on an external workstation (AW 4; GE 
Healthcare). 
Full body CT scanning was performed on the same CT scanner using 100 ml iodixanol. 
 
SPECT imaging 
For assessment of myocardial perfusion, 99mTC (10 MBq / kg) was injected into the ear 
vein and images were acquired over 5 minutes on the SPECT part of a hybrid SPECT-CT 
scanner (Discovery NM CT 570c, GE Healthcare) integrating a 64-slice CT-device and a 
CIRCULATIONAHA/2011/087684 
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cadmium-zinc-telluride (CZT) gamma camera. The CZT camera has been extensively 
described recently.24, 25 Briefly, it is a gamma detector with a pinhole collimator and 19 
stationary detector modules positioned around the chest. For perfusion imaging a 
symmetric energy window of at 140 kiloelectron volt (keV) ± 5 % was used, while for dual 
peak acquisition with 123I a window at 159 keV ± 5 % was added. 
For mid (5 days after transplantation) and long term (12 - 15 weeks after transplantation) 
detection of transplanted hiPSCs, 123I was injected intracoronary into each main coronary 
artery (LAD, LCX, RCA) using an over the wire balloon catheter during three coronary 
occlusions, each lasting 2-3 min. Between occlusions, the coronary artery was reperfused 
for 2 min. Afterwards, animals underwent SPECT-CT imaging as described above. 
See also Supplemental Figure 2 for details. 
 
(Immuno-)histological analysis 
See details in supplements. 
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Results 
Functional sodium iodide symporter expression in transgenic hiPSC clones 
hiPSCs (clone hCBiPSC2)1 were co-transfected with the bicistronic vector 
pCAG_rNIS_IRES2_Venus_nucmem (Figure 1A) and the plasmid 
αMHCneoPGKhygro26, enabling selection of hygromycin resistant transgenic cell clones. 
6 independent Venuspos clones (designated rNIS clone 1, 2, 4, 5, 6, 7) were analysed for 
stability of transgene expression. Flow cytometry and fluorescence microscopy revealed 
robust and stable Venus expression for up to 23 passages with line-specific variations 
(Figure 1B&C). Venus-specific immunohistological assessment was also performed on 
paraffin sections of suspension culture-derived cell aggregates and differentiated cells in 
embryoid bodies. In contrast to the expected Venus fluorescence signal in the nucleus of 
viable cells (Figure 1C), cytoplasmic staining was noted post fixation and 
immunohistochemistry (Figure 1D left panel), however, staining specificity was proven by 
isotype- (Figure 1D right panel) and non-transgenic cell controls (data not shown). 
Quantitative RT-PCR revealed co-expression of the NIS-transgene in Venus expressing 
clones (data not shown). Venus protein expression was demonstrated in undifferentiated 
as well as differentiated cells of the NISpos-hiPSC clone 6 including hiPSC-derived 
CD31pos endothelial cells (Supplemental Figure 3). Further analyses and all cell 
transplantation experiments were conducted using the NISpos-hiPSC clone 6. 
Transgenic cells and control hiPSCs were analysed for NIS-specific iodide uptake by in 
vitro incubation with 125I, an isotope with a half-life of 13 hours. Intracellular labeling 
efficiency depends on the effective half-life of an applied isotope and the cells’ kinetics of 
respective isotope accumulation. 125I uptake in NISpos-hiPSCs reached a plateau after ~ 
90 min. After vigorous washing 125I accumulation was ~ 100 times higher than for non-
transgenic hiPSC control cells (Figure 1E). Importantly, iodide uptake was completely 
blocked by the specific NIS-inhibitor perchlorate. Typically, the majority of accumulated 
125I was released to the medium within 2 h (Figure 1F). Notably, neither NIS expression 
CIRCULATIONAHA/2011/087684 
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nor radiolabeling of NISpos-hiPSCs did affect the cell viability (Supplemental Figure 4). 
 
Successful SPECT-CT-based detection of down to 1x105 123I-labelled NISpos-hiPSCs 
in explanted pig hearts 
Ex vivo cardiac SPECT-CT was performed to determine the detection limit for 123I–pre-
labelled NISpos-hiPSCs after intramyocardial cell injection. Equal volumes of a serial 
dilution of labelled cells were applied. As shown in Figure 3, SPECT-CT enabled 
detection of a minimum of 1 x 105 cells injected into explanted pig hearts. Notably, 123I 
tracer uptake was detected through a dissected pig chest that had been placed above the 
heart to mimic signal attenuation in vivo. Based on these results 5 x 107 pre-labelled 
NISpos-hiPSC were subsequently applied in vivo per injection areal with a hypothetic 
detection threshold of ~ 2 % persistent cells. 
 
Pre-labelled NISpos-hiPSCs were detected for up to 5 hours after catheter-based 
intramyocardial delivery into distinct regions of infracted hearts 
As indicated in the study design (Figure 2), myocardial infarction was induced in 13 
animals, 10 of which were enrolled in the study. Ten days after transient occlusion of the 
LAD, SPECT-CT imaging revealed perfusion defects in the apex and mid-segment of the 
anterior and septal wall in all treated animals (Figure 4, 1st line). This was also confirmed 
by NOGA™ mapping demonstrating loss of electrical activity at the apicoseptal, 
apicobasal and apicolateral myocardial regions (red colour). Brown points represent the 
locations of the NOGA™-guided intramyocardial injections at the border zone of infarction 
(Figure 4, 2nd line; Supplemental Figure 5). One to three hours after injection of 123I pre-
labelled NISpos-hiPSCs (5 x 107 hiPSCs, or 5 x 107 hiPSCs co-administered with 5 x 107 
human MSCs, respectively, per injection area), intensive 123I signals were detected by 
SPECT-CT imaging in the septal and lateral wall of the left ventricle corresponding 
exactly to the injection site as recorded by NOGA™-mapping. As expected, 123I treated 
control cells injected into a separate region of the same heart did not result in a 
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detectable SPECT signal (Figure 4, 3rd line). Notably, MSC co-administration 
considerably increased signal intensity suggesting improved hiPSC retention in the 
myocardium after transplantation (Figure 4 and Supplemental Online Video 1). The 
signal intensity was highest in the first hour after cell transplantation and diminished 
successively. At 3 - 5 hours post injection signal intensity was substantially reduced 
(Supplemental Figure 6) and became undetectable after 24 h (data not shown). Imaging 
of control animals treated with PBS did not show any SPECT signal (data not shown). As 
expected, immunohistological staining of tissue sections of the region where NISpos-
hiPSCs and human MSCs had been co-injected, showed an injection channel filled with 
rounded cells containing a fraction of Venuspos and OCT4pos cells (Figure 4). A 
semiquantitative analysis of the obtained 123I signals in the two pigs that have been 
sacrificed after day 1 follow up demonstrated that the NISpos-hiPSCs co-transplanted with 
MSCs gave a 6.8-fold / 1.7-fold stronger 123I signal than the separately transplanted 
NISpos-hiPSC cells (Supplemental Figure 7). No detectable 123I activity was associated 
with the transplanted NISneg control cells. These results are now presented in 
Supplemental Table 1 of the revised manuscript. 
 
Long term detection of engrafted NISpos-hiPSC derivatives for up to 15 weeks by 
SPECT-CT imaging following intracoronary iodide administration 
For detection of transplanted NISpos-hiPSC derivatives at 5 days and 12 - 15 weeks post 
intramyocardial cell injection, 123I was infused intracoronary via LAD, LCX and RCA. One 
hour after tracer injection, the resulting 123I signals were assessed. As expected, in 
SPECT-CT a very strong uptake was observed in the thyroid while a weaker uptake was 
detected in the stomach (data not shown). Interestingly, in the heart, 123I signals were 
detected exclusively in regions where NISpos-hiPSCs had been co-transplanted with 
human MSCs (Figure 5). In independent hearts, 123I accumulation was either detected in 
the lateral heart region or in the septal left ventricular wall, respectively, always 
correlating with the area of NISpos-hiPSC / MSC co-injection. In contrast, no 123I signal 
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could be detected in regions where NISpos-hiPSCs only or control cells had been injected. 
In vitro co-culture experiments under hypoxic conditions were performed, in order to 
investigate whether anti-apoptotic effects of MSCs might support the survival of NIS-
hiPSCs. Interestingly, MSCs significantly decreased the rate of NIS-hiPSCs apoptosis. 
This effect was dependent of both secreted factors and cell-cell contact (Supplemental 
Figure 8). 
After SPECT-CT, hearts were sacrificed for tissue sample analysis. In correlation with 
SPECT-CT imaging and NOGA-mapping of myocardial infarction, histological analyses of 
respective heart regions (collected 5 days and 15 weeks after cell transplantation) 
revealed typical signs of infarction and subsequent fibrosis including widespread 
replacement of myocardium through loose to densely arranged cells with fibroblast 
phenotype, and moderate presence of granulocytes and lymphocytes. 
Immunohistochemistry confirmed persistent engraftment of NISpos-hiPSCs. Anti-Venus-
specific staining demonstrated the presence of Venuspos hiPSC derivatives 5 days and 12 
/ 15 weeks after cell injection. Notably, after 12 / 15 weeks the histological images 
suggest that hiPSC derivatives had adopted an endothelial phenotype lining numerous 
vessels in the injected heart regions (see Figure 5 right panel, Supplemental Figure 9). 
Complementing semi-quantitative analyses on the capillary densities of the respective 
heart regions suggested an increased capillary density in the regions of NISpos-hiPSC-
MSC versus NISpos-hiPSC injection (Supplemental Figure 10). Interestingly, in contrast 
to analysis 5 hours post cell administration, no OCT4-specific cell staining could be 
detected at 5 days or 12 / 15 weeks (data not shown). Also, no teratoma or other obvious 
tumor formation was detected in the sacrificed recipient animals during autopsy. 
 
Discussion 
The availability of transgene-based imaging technologies in large animals that enable 
non-toxic, specific, sensitive, non-invasive and serial long term imaging of viable grafts is 
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of utmost importance for pre-clinical evaluation of stem cell based therapies. 
 We have here established a reporter gene approach that enables in vivo monitoring 
of long term survival of human iPSC derivatives in a pig model of myocardial infarction. 
Notably, this is the first report demonstrating the feasibility of repeated longitudinal in vivo 
imaging of cell viability, proliferation and tissue distribution of cellular grafts in internal 
organs of large animals. 
 Similar to luciferase imaging in small animals, viable cells expressing NIS are able 
to accumulate 123I and to evoke a detectable SPECT signal, thereby preventing false 
positive detection of dead cells, cell debris-bound label or phagocytosing macrophages. 
Although the ratio of the intensity of the specific 123I signal in our NISpos-hiPSCs compared 
to NISneg hiPSCs as determined in vitro is lower than the typical signal to background 
ratio in case of luciferase reporter systems, long term surviving NISpos-hiPSCs derivatives 
evoked a 123I signal of considerable intensity in the areas of intramyocardial cell injection. 
This may be explained by the relatively low absorption of the 123I signal through soft and 
hard tissue and is in contrast to the very limited tissue penetration of luciferin emitted 
light, which, even in small animals with low tissue thickness, leads to significant loss of 
signal. 
 Ex vivo injection of 123I-labelled NISpos-hiPSCs revealed a detection limit of ~ 1 x 105 
cells in isolated pig hearts. Since 123I signals were recorded through an isolated pig chest, 
one can expect signal intensities in vivo in the same range as those detected in hearts 
assessed ex vivo. Although not directly comparable, because i) lentiviral vectors and 
another tracing approach were used, ii) another stem cell type, namely cardiac stem 
cells, was applied, and iii) signal retention through pig chest is slightly different from 
retention by a rat chest, the determined detection limit is in the same range than for cell 
transplantation into rat hearts. Here, Terrovitis et al.19 estimated 1.5 x 105 as minimal 
detectable cell number. Further advantages of hNIS-SPECT versus HSVtk-PET imaging 
are the wide availability of the necessary tracers and lack of need for specialized 
radiosynthesis facilities, and the lack of immunogenicity of the human NIS, which may be 
CIRCULATIONAHA/2011/087684 
 
 
17
of critical importance especially for long term monitoring. 
 Obviously, SPECT imaging of NIS-expressing cell grafts has limitations. As every in 
vivo imaging approach, there is a detection limit in terms of a minimal detectable number 
of cells. Certainly, we cannot exclude distribution of single undifferentiated or 
differentiated hiPSC derivatives to other organs. Indeed, only if a critical number of cells 
accumulate or is reached due to local proliferation, the minimal detection limit at a 
specific site is achieved, NIS-expressing engrafted cells can be detected. Nevertheless, 
in our experiments, we were not able detect any 123I signals outside the heart despite the 
naturally NIS expressing tissue sites. Autopsies of the sacrificed animals 12 - 15 weeks 
after cell infusion confirmed these results and did not reveal any sign of tumour or 
teratoma formation. Together with the absence of OCT4pos cells 12 - 15 weeks after cell 
transplantation as analysed by immunohistochemistry, this raises the question whether 
the high incidence of teratomas observed in immunoincompetent mice are actually 
indicative for clinical applications, or rather an artefact of species incompatibilities that 
prevent natural control of cell proliferation in the specific tissue niches. Another potential 
explanation for the obvious absence of undifferentiated cells and the observed parallel 
persistence of differentiated vascular NISpos-hiPSC derivatives might be the applied 
immunosuppressive protocol consisting of relative high doses of cyclosporine A (CsA) 
and prednisolone. In general, the long term persistence of hiPSC-derived endothelial 
cells indicates the efficacy of our immunosuppressive protocol, at least in terms of T-cell 
reactivity towards differentiated iPSC derivatives. However, there is evidence that CsA is 
not effective towards natural killer (NK) cells,27 which might lead to selective NK cell-
based erasure of undifferentiated pluripotent stem cells.28 In case of prednisolone, recent 
data suggest that inhibition of NK cells depends on the mode of activation thereby 
indicating that prednisolone treatment might also not fully prevent NK-mediated killing of 
undifferentiated hiPSCs.29 
 Another limitation of this imaging technology is the physiological expression of NIS 
in the thyroid, stomach, choroids plexus, and salivary gland. As the signals from these 
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organs are strong, they may cover up weak signals from adjacent organs. For instance, 
although not posing a problem in larger animals such as the pig, the strong thyroid signal 
may interfere with close-by cardiac tracer signals in mice. Also, the stomach background 
signal may interfere with tracer signals in the upper abdomen. 
 Of course, there is room for further improvements: Higher levels of NISpos 
expression in optimized vector systems and selected stable cell clones might lead to 
further increase of 123I accumulation compared to NISneg control cells. In addition, we do 
currently not know, whether potential silencing effects during in vivo differentiation of the 
transplanted NISpos-hiPSCs might have diminished NIS expression in our experiments, 
and whether expression systems with reduced silencing can lead to further increase of 
the 123I signal. 
As mentioned above, immunohistochemical staining of myocardial tissue sections 
harvested 5 days and 12 - 15 weeks after cell application showed no OCT4pos cells in the 
areas of previous cell infusion. Instead, Venuspos NISpos-hiPSC derivatives with 
endothelial phenotype were detected, which contributed to the intramyocardial 
vasculature. Notably, the utilized CAG promoter driven NIS does not allow following 
differentiation events through SPECT imaging. However, this could be realized through 
placing NIS under control of cell-type specific promoters, for instance the OCT4 
promoter5 or the cardiomyocyte specific αMHC promoter.30 
 Of importance for future clinical application of this technology will be the use of well 
characterised transgenic cell clones with defined transgene integration through zinc finger 
or TALE nuclease,31 for instance, in safe harbour sites such as adeno-associated virus 
integration site 1 (AAVS1),31 thereby diminishing risks of insertional mutagenesis and 
carcinogenesis. Importantly, it has to be assessed whether the required level of radiation 
can be reduced: Although the applied 123I dose is on a similar level than clinically applied 
for standard tumor therapies, it is far higher than for routine thyroid diagnostics thereby 
prohibiting clinical application of the developed approach at this stage. Furthermore, and 
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although the conducted minimal invasive cell application by intramyocardially hiPSC 
injection is of high clinical relevance, it has to be evaluated whether similar or even higher 
sensitivities and signal-to-noise ratios can be obtained in case of global tracer delivery for 
instance through the pig’s ear veins. 
 As a first application of the established technology for SPECT imaging of transgenic 
NIS expression, we have addressed the common problem of low cell survival and 
retention rates after cell transplantation.8-10 Typically, after intramyocardial cell infusion 
the majority of donor cells are directly flushed back through the injection channel10, 32 or 
do not survive the initial phase after transplantation.9 To address this problem, Laflamme 
et al. recently described a novel pro-survival cocktail that can dramatically increases 
engraftment of transplanted human embryonic stem cell derived cardiomyocytes in a 
athymic rat model.8 We have now investigated whether co-transplantation of human 
MSCs that release antiapoptotic factors33 and express immunomodulatory properties34 
may improve the survival and engraftment of transplanted NISpos-hiPSCs after 
xenotransplantation into pigs. Interestingly, SPECT imaging suggested a positive effect of 
the co-transplanted human MSCs even 3 hours after cell infusion showing a markedly 
stronger tracer uptake at the sites where NISpos-hiPSCs had been co-transplanted with 
human MSCs, than at the injection sites of pure NISpos-hiPSCs. It is questionable, 
whether this very early phenomenon can be explained through anti-apoptotic effects. It is 
more likely that other effects including MSC-mediated increased cell aggregation, which 
may favour engraftment and diminish the flush out of transplanted cells, are responsible 
for this effect. However, in the mid and long term (5 days and 12 - 15 weeks), NISpos-
hiPSCs could be detected exclusively at the site of co-injection, indicating an additional 
profound effect on long term engraftment of NISpos hiPSCs. Certainly, deciphering the 
underlying mechanisms will require extensive additional investigations but will be of 
utmost importance to optimize MSC-supported survival of hiPSC derivatives. 
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Conclusions 
This is the first study demonstrating the usefulness of the sodium iodide symporter (NIS) 
for serial long term tracking of survival, engraftment and distribution of cellular grafts in a 
large animal model using SPECT-CT imaging. Moreover, for the first time we 
demonstrate long term survival and differentiation of human iPSCs in a preclinical pig 
model of myocardial infarction. The applied three dimensional (3D) hybrid imaging 
protocol enables combined assessment of cardiac anatomy, myocardial perfusion and 
monitoring of donor cell survival, proliferation and distribution within one imaging modality 
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Figure legends 
 
Figure 1: Generation and functional characterization of NISpos-hiPSCs 
(A) Map of the bicistronic vector pCAG_rNIS_IRES2_Venus_nucmem used for the 
generation of transgenic hiPSC clones.  
(B) FACS analysis of Venus expression in several independent rNISpos-hiPSC clones. 
Individual clones showed a stable level of transgene expression for up to 23 passages. 
(C) Overlay of fluorescence and phase contrast image revealing the expected nuclear 
Venus localization of a typical NISpos-hiPSC colony cultured on matrigel (clone 6, 6 
passages after clonal selection). 
(D) Detection of Venus by immunohistochemistry on a section of PFA-fixed NISpos-hiPSC 
aggregates derived from suspension culture, and the respective isotope control. For 
immunostaining, an anti-GFP antibody was used, which crossreacts with the yellow GFP 
variant Venus. Notably, fixation and immunohistochemistry treatments leads to an 
apparently cytoplasmic Venus-specific staining, which is in contrast to the direct Venus 
fluorescence in viable cells that is strictly restricted to the nuclear membrane as shown in 
(C). 
(E) Kinetics of 125I uptake by NISpos-hiPSCs (clone 6), inhibition by 100µM perchlorate, 
and NISneg-hiPSC controls (mean ± SEM, triplicate measurements). Iodide uptake 
reached a steady state within 90 min with a max concentration of ~ 100-fold above 
background in negative controls. 125I accumulation in NISpos-hiPSCs was completely 
abolished by perchlorate suggesting specificity of the signal. 
(F) Kinetic of iodide retention in NISpos-hiPSCs (mean ± SEM, triplicate measurements). 
 
Figure 2: Study design 
CsA = cyclosporin A, iPSCs = induced pluripotent stem cells; MI = myocardial infarction 
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Figure 3: Ex vivo SPECT-CT of pig hearts transplanted with NISpos-hiPSCs 
123I-prelabeled NISpos-hiPSCs were transplanted into pig hearts ex vivo in order to 
determine the minimal number of detectable NISpos-hiPSCs. Depicted are SPECT-CT 
images of pig hearts after injections of equal volumes with different amounts of cells as 
indicated: 1 = 1.2 x 107; 2 = 6 x 106; 3 = 3 x 106; 4 = 1 x 106; 5 = 5 x 105; 6 = 1 x 105; 7 = 1 
x 104. Injected NISpos-hiPSCs were detectable down to 1 x 105 cells. 
 
Figure 4: In vivo cardiac hybrid-SPECT-CT demonstrates successful induction of 
myocardial infarction and suggests long term survival of NISpos-hiPSC grafts 
Representative images of a heart of one of three recipient animals that were sacrificed 6 
h after cell injection are shown. 
1st line: SPECT-CT in vivo imaging of the left ventricle demonstrates a loss of myocardial 
perfusion (blue) in the anteroapical and septal wall after occlusion of the LAD. Non-
infarcted myocardium appears orange coloured indicating normal 99mTC-tetrofosmin 
uptake. 
2nd line: Three-dimensional NOGA™ mapping of the left ventricle recorded during cell 
injection. NOGA™ colours represent unipolar voltage values, red = scar, green to blue = 
viable tissue. Cell injection sites in the lateral (NISpos-hiPSCs + MSCs), septal (NISpos-
hiPSCs) and anterior (non-transgenic MSCs) walls are shown as brown dots. 
3rd line: SPECT-CT imaging of left ventricle 1 h after catheter-based intramyocardial cell 
injection demonstrating intense 123I signals (yellow) in the lateral and septal wall that 
correspond exactly to the injection sites (each injection area 5 x 107 hiPSCs) as recorded 
by NOGA™ mapping; control cells did not result in a detectable radiotracer signal (anterior 
wall). Co-administration of MSCs markedly increased signal intensity (lateral wall). 
Immunohistochemistry: Depicted are immunohistological sections of the lateral ventricle 
wall showing a cell injection channel 6 h after cell application filled with co-transplanted 
hMSCs and Venuspos NISpos-hiPSCs stained for Venus and OCT4 (each with brown 
colour) 
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Figure 5: In vivo SPECT-CT imaging of long term surviving derivatives of NISpos-
hiPSCs in pig hearts after 5 days and 15 weeks, respectively 
Non-pre-labelled NISpos-hiPSCs (each site 5x107 cells) could be detected in mid-term (5 
days) and long term follow up (15 weeks) ~ 1h after intracoronary 123I injection. 
Immunohistochemical staining of tissue sections of corresponding areas of the left 
ventricular wall confirmed the presence of Venuspos (stained with crossreacting anti GFP 
antibody) NISpos-hiPSC derivatives. Notably, the vast majority of Venuspos iPSC 
derivatives were found to represent endothelial cells integrated into the cardiac 
vasculature 15 weeks after cell transplantation. No OCT4pos cells could be detected (data 
not shown). The 123I-signal intensities as determined by volume of interest analysis (VOI) 
of the respective animals shown are as follows: 5 days post injection animal: VOI = 4.3 x 
105 counts (septal region = NISpos-hiPSC + MSC injection); 15 weeks post injection 
animal: VOI = 1.8 x 105 counts (lateral region = NISpos-hiPSC + MSC injection). 
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